AntibodySystem는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
Research Grade Motavizumab
제품 번호
DVV02803
제품 특징
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
DVV02803
Humanized
HRSV-A
Liquid
0.01M PBS, pH 7.4.
1.12 mg/ml
>95% by SDS-PAGE.
Monoclonal
IgG1, kappa
Research Grade Biosimilar
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Protein A/G purified from cell culture supernatant.
Please contact with the lab for this information.
XtenCHO
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3, Human Respiratory Syncytial Virus (HRSV)
For research use only. Not suitable for clinical or therapeutic use.
Data Image
AntibodySystem의 모든 제품들을 만나 보세요!
{ const originalImageSrc = iconImages[index].src; li.addEventListener('mouseenter', () => { iconImages[index].src = originalImageSrc.replace('.png', '_w.png'); }); li.addEventListener('mouseleave', () => { iconImages[index].src = originalImageSrc; }); }); function goBack(){ window.history.back(); }